Nanexa AB (publ) (NANEXA.ST)
SEK 2.54
(-5.22%)
SEK 2.54
(-5.22%)
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2023 | 2.08 Million SEK | -48.7% |
| 2022 | 4.06 Million SEK | 58.1% |
| 2021 | 2.57 Million SEK | -9.72% |
| 2020 | 2.85 Million SEK | -26.66% |
| 2019 | 3.88 Million SEK | -21.98% |
| 2018 | 4.98 Million SEK | 59.56% |
| 2017 | 3.12 Million SEK | 81.01% |
| 2016 | 1.72 Million SEK | 589.86% |
| 2015 | 250 Thousand SEK | 87.97% |
| 2014 | 133 Thousand SEK | 0.0% |
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2024 Q2 | 1.53 Million SEK | -15.95% |
| 2024 Q1 | 1.83 Million SEK | -12.27% |
| 2023 Q2 | 2.96 Million SEK | -15.67% |
| 2023 Q4 | 2.08 Million SEK | -13.58% |
| 2023 FY | 2.08 Million SEK | -48.7% |
| 2023 Q1 | 3.51 Million SEK | -13.54% |
| 2023 Q3 | 2.41 Million SEK | -18.58% |
| 2022 Q2 | 5.66 Million SEK | 145.64% |
| 2022 Q3 | 4.55 Million SEK | -19.64% |
| 2022 FY | 4.06 Million SEK | 58.1% |
| 2022 Q4 | 4.06 Million SEK | -10.67% |
| 2022 Q1 | 2.3 Million SEK | -10.34% |
| 2021 Q3 | 2.88 Million SEK | -13.33% |
| 2021 Q1 | 2.59 Million SEK | -9.09% |
| 2021 Q2 | 3.33 Million SEK | 28.6% |
| 2021 FY | 2.57 Million SEK | -9.72% |
| 2021 Q4 | 2.57 Million SEK | -10.91% |
| 2020 Q4 | 2.85 Million SEK | -8.33% |
| 2020 FY | 2.85 Million SEK | -26.66% |
| 2020 Q2 | 3.36 Million SEK | -7.14% |
| 2020 Q1 | 3.62 Million SEK | -6.66% |
| 2020 Q3 | 3.1 Million SEK | -7.69% |
| 2019 Q2 | 4.43 Million SEK | -5.84% |
| 2019 Q3 | 4.15 Million SEK | -6.21% |
| 2019 FY | 3.88 Million SEK | -21.98% |
| 2019 Q4 | 3.88 Million SEK | -6.5% |
| 2019 Q1 | 4.7 Million SEK | -5.52% |
| 2018 Q3 | 2.55 Million SEK | -17.28% |
| 2018 FY | 4.98 Million SEK | 59.56% |
| 2018 Q1 | 3.1 Million SEK | -0.5% |
| 2018 Q2 | 3.09 Million SEK | -0.52% |
| 2018 Q4 | 4.98 Million SEK | 94.87% |
| 2017 Q4 | 3.12 Million SEK | -2.48% |
| 2017 FY | 3.12 Million SEK | 81.01% |
| 2017 Q3 | 3.2 Million SEK | -0.09% |
| 2017 Q2 | 3.2 Million SEK | 86.82% |
| 2017 Q1 | 1.71 Million SEK | -0.56% |
| 2016 FY | 1.72 Million SEK | 589.86% |
| 2016 Q1 | 252 Thousand SEK | 0.8% |
| 2016 Q2 | 245 Thousand SEK | -2.78% |
| 2016 Q4 | 1.72 Million SEK | 633.89% |
| 2016 Q3 | 235 Thousand SEK | -4.08% |
| 2015 FY | 250 Thousand SEK | 87.97% |
| 2015 Q3 | 313 Thousand SEK | 4.33% |
| 2015 Q4 | 250 Thousand SEK | -20.13% |
| 2015 Q2 | 300 Thousand SEK | 0.0% |
| 2015 Q1 | - SEK | 0.0% |
| 2014 FY | 133 Thousand SEK | 0.0% |
| 2014 Q4 | - SEK | 0.0% |
| Name | Long Term Debt | Long Term Debt Difference |
|---|---|---|
| AcuCort AB | - SEK | -Infinity% |
| AlzeCure Pharma AB (publ) | - SEK | -Infinity% |
| BioGaia AB (publ) | 26.35 Million SEK | 92.081% |
| Enzymatica AB (publ) | 24.88 Million SEK | 91.613% |
| Enorama Pharma AB (publ) | 303 Thousand SEK | -588.779% |
| Gabather AB (publ) | - SEK | -Infinity% |
| Klaria Pharma Holding AB (publ.) | - SEK | -Infinity% |
| Moberg Pharma AB (publ) | 3.46 Million SEK | 39.804% |
| Newbury Pharmaceuticals AB (publ) | - SEK | -Infinity% |
| ODI Pharma AB | - SEK | -Infinity% |
| Orexo AB (publ) | 448.4 Million SEK | 99.535% |
| Probi AB (publ) | 38.21 Million SEK | 94.538% |
| Swedencare AB (publ) | 1.44 Billion SEK | 99.855% |
| Swedish Orphan Biovitrum AB (publ) | 11.35 Billion SEK | 99.982% |
| Toleranzia AB | 850 Thousand SEK | -145.529% |
| Vivesto AB | 5.18 Million SEK | 59.718% |